BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 3.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,906 shares of the biotechnology company’s stock after selling 416 shares during the period. Crossmark Global Holdings Inc.’s holdings in BioMarin Pharmaceutical were worth $848,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. ProShare Advisors LLC boosted its stake in shares of BioMarin Pharmaceutical by 56.4% in the second quarter. ProShare Advisors LLC now owns 20,677 shares of the biotechnology company’s stock worth $1,702,000 after acquiring an additional 7,456 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in BioMarin Pharmaceutical by 61.6% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 36,343 shares of the biotechnology company’s stock worth $2,992,000 after purchasing an additional 13,853 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of BioMarin Pharmaceutical by 144.3% during the second quarter. AQR Capital Management LLC now owns 55,372 shares of the biotechnology company’s stock worth $4,559,000 after buying an additional 32,709 shares in the last quarter. MBB Public Markets I LLC acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $987,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of BioMarin Pharmaceutical by 177.7% in the second quarter. The Manufacturers Life Insurance Company now owns 180,617 shares of the biotechnology company’s stock worth $14,870,000 after buying an additional 115,578 shares in the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 5,278 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total value of $350,300.86. Following the completion of the transaction, the executive vice president now owns 68,909 shares in the company, valued at approximately $4,573,490.33. This trade represents a 7.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN opened at $61.73 on Friday. The company has a market cap of $11.76 billion, a P/E ratio of 36.96, a P/E/G ratio of 0.54 and a beta of 0.29. BioMarin Pharmaceutical Inc. has a 1-year low of $60.63 and a 1-year high of $94.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The stock has a 50-day moving average of $65.12 and a two-hundred day moving average of $73.71.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The business had revenue of $746.00 million for the quarter, compared to analysts’ expectations of $703.37 million. During the same period in the previous year, the company earned $0.26 earnings per share. BioMarin Pharmaceutical’s quarterly revenue was up 28.4% on a year-over-year basis. As a group, analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.5 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on BMRN shares. William Blair downgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 30th. Wedbush raised BioMarin Pharmaceutical to a “strong-buy” rating in a report on Monday, November 4th. Barclays reduced their price objective on BioMarin Pharmaceutical from $110.00 to $86.00 and set an “overweight” rating on the stock in a research report on Friday, October 4th. Raymond James restated an “outperform” rating and issued a $79.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, October 10th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $80.00 price target on shares of BioMarin Pharmaceutical in a research report on Wednesday, October 30th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.